Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-Producing<i>Escherichia Coli</i>-Related Complicated Lower Urinary Tract Infection

Şenol, Şebnem; Taşbakan, Meltem; Pullukçu, Hüsnü; Sıpahi, Oğuz Reşat; Sipahi, Hilal; Yamazhan, Tansu; Arda, Bilgin; Ulusoy, Sercan

doi:10.1179/joc.2010.22.5.355

Cited by 70 publications

(70 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a small observational study of patients with complicated lower UTI due to ESBL-producing E. coli, oral fosfomycin trometamol was compared with carbapenem treatment. Clinical and microbiological success with fosfomycin and carbapenems was not significantly different (77.8% versus 95% and 59.3% versus 80%, respectively; P Ͼ 0.05) (229). In addition, a discordance between in vitro susceptibility to fosfomycin and microbiological effectiveness was observed in patients with P. aeruginosa (75% versus 38%) and CR K. pneumoniae UTIs (92% versus 46%) (230).…”

Section: Urinary Tract Infectionsmentioning

confidence: 87%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

SUMMARYThe treatment of bacterial infections suffers from two major problems: spread of multidrug-resistant (MDR) or extensively drug-resistant (XDR) pathogens and lack of development of new antibiotics active against such MDR and XDR bacteria. As a result, physicians have turned to older antibiotics, such as polymyxins, tetracyclines, and aminoglycosides. Lately, due to development of resistance to these agents, fosfomycin has gained attention, as it has remained active against both Gram-positive and Gram-negative MDR and XDR bacteria. New data of higher quality have become available, and several issues were clarified further. In this review, we summarize the available fosfomycin data regarding pharmacokinetic and pharmacodynamic properties, thein vitroactivity against susceptible and antibiotic-resistant bacteria, mechanisms of resistance and development of resistance during treatment, synergy and antagonism with other antibiotics, clinical effectiveness, and adverse events. Issues that need to be studied further are also discussed.

show abstract

Section: Urinary Tract Infectionsmentioning

confidence: 87%

Fosfomycin

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In European countries similar rates have been reported. [13] Şenol et al [19] compared fosfomycin, and carbapenem in the treatment of complicated lower UTIs caused by E. coli, and despite comparable clinical, and microbiological success rates, the authors reported favourable cost-effectiveness with fosfomycin treatment. Fosfomycin appears to be an effective alternative in the current treatment of community-acquired urinary system infections thanks to ease of single dose applications, better patient compliance, lower complication rates, and its safe use in children, and pregnants.…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014)

Yılmaz¹,

Ağuş²,

Bayram³

et al. 2016

Turkish Journal of Urology

View full text Add to dashboard Cite

Objective: Urinary tract infections (UTIs) are among the most frequently seen community-acquired infections worldwide. E. coli causes 90% of urinary system infections. To guide the empirical therapy, the resistance pattern of E. coli responsible for community-acquired UTI was evaluated throughout a seven-year period in this study. Material and methods:The urine cultures of patients with urinary tract infections admitted to outpatient clinics between 1 st January 2008 and 31 st December 2014 were analyzed. Presence of ≥10 5 colony-forming units/mL in urine culture media was considered as significant for UTI. Isolated bacteria were identified by standard laboratory techniques or automated system VITEK2 (BioMerieux, France) and BD PhoenixTM 100 (BD, USA), as required. Antibiotic susceptibility testing was performed by Kirby-Bauer disk diffusion method using Clinical Laboratory Standard Institute (CLSI) criteria.Results: A total of 13281 uropathogens were isolated. Overall E. coli accounted for 8975 (67%) of all isolates. Resistance rates of E. coli to antimicrobial agents was demonstrated to be as follows: ampicillin 66.9%, cefazolin 30.9%, cefuroxime 30.9%, ceftazidime 14.9%, cefotaxime 28%, cefepime 12%, amoxicillin-clavulanic acid 36.9%, trimethoprim-sulfamethoxazole (TMP-SXT) 20%, ciprofloxacin 49.9%, amikacin 0.3%, gentamycin 24%, nitrofurantoin 0.9%, and fosfomycin 4.3%. There was no resistance to imipenem nor meropenem. The frequency of ESBL-producing E. coli strains was 24%. Conclusion:It is concluded that fosfomycin and nitrofurantoin are appropriate empirical therapy for community-acquired UTI empirical therapy, but the fluoroquinolones and the TMP-SXT shall not be used in the emprical treatment of UTI at this stage. In conclusion, as resistance rates show regional differences, it is necessary to regularly examine regional resistance rates to determine the appropriate empiric antibiotic treatment and national antibiotic usage policies must be reorganized according to data obtained from these studies.

show abstract

“…Frequently it retains good in vitro activity against ESBL-producing E. coli and K. pneumoniae [de Cueto et al 2006;Maraki et al 2009;Falagas et al 2010a]. Observational studies have shown that fosfomycin is effective for the treatment of lower UTIs due to ESBL-producing Enterobacteriaceae Senol et al 2010] and is our preferred therapy for such infections. There is very limited experience in the use of intravenous fosfomycin for invasive infections.…”

Section: Other Antimicrobialsmentioning

confidence: 99%

Clinical management of infections caused by multidrug-resistant Enterobacteriaceae

Delgado-Valverde

Sojo-Dorado

Pascual

2013

Therapeutic Advances in Infection

View full text Add to dashboard Cite

Enterobacteriaceae showing resistance to cephalosporins due to extended-spectrum b-lactamases (ESBLs) or plasmid-mediated AmpC enzymes, and those producing carbapenemases have spread worldwide during the last decades. Many of these isolates are also resistant to other first-line agents such as fluoroquinolones or aminoglycosides, leaving few available options for therapy. Thus, older drugs such as colistin and fosfomycin are being increasingly used. Infections caused by these bacteria are associated with increased morbidity and mortality compared with those caused by their susceptible counterparts. Most of the evidence supporting the present recommendations is from in vitro data, animal studies, and observational studies. While carbapenems are considered the drugs of choice for ESBL and AmpC producers, recent data suggest that certain alternatives may be suitable for some types of infections. Combined therapy seems superior to monotherapy in the treatment of invasive infections caused by carbapenemase-producing Enterobacteriaceae. Optimization of dosage according to pharmacokinetics/pharmacodynamics data is important for the treatment of infections caused by isolates with borderline minimum inhibitory concentration due to lowlevel resistance mechanisms. The increasing frequency and the rapid spread of multidrug resistance among the Enterobacteriaceae is a true and complex public health problem. IntroductionThe traditional first-line available options for treating serious infections caused by enterobacteria include penicillins, cephalosporins, monobactams, carbapenems, fluorquinolones, and in certain situations, aminoglycosides. The frequency of resistance to these first-line agents has been rising worldwide during the last decades [Paterson 2006;Rhomberg and Jones 2009;Houghton et al. 2010;Nordmann, et al. 2011] and now reach high proportions in many areas of the world.

show abstract

Carbapenem Versus Fosfomycin Tromethanol in the Treatment of Extended-Spectrum Beta-Lactamase-ProducingEscherichia Coli-Related Complicated Lower Urinary Tract Infection

Cited by 70 publications

References 8 publications

Fosfomycin

Fosfomycin

Antimicrobial susceptibilities of Escherichia coli isolates as agents of community-acquired urinary tract infection (2008-2014)

Clinical management of infections caused by multidrug-resistant Enterobacteriaceae

Contact Info

Product

Resources

About